Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Discussion on the latest research for using bisphosphonates to treat cancer metastasis

NCRI

Published: 10 Nov 2009

Views: 12072

Rating:

Save

Professor Robert Coleman - Cancer Research Centre, Academic Unit of Clinical Oncology, Weston Park Hospital

Categories:
Biology

Related Videos

The somatic mutation profile of breast cancer in Uganda

Dr Manoj Menon - Fred Hutchinson Cancer Center, Seattle, USA

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine...

Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine improves PFS in N2-3 nasopharyngeal carcinoma ( Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China )

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

Prognostic value of HER2-low status in breast cancer: A systematic review and...

Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )

Dostarlimab chemo combo for primary advanced or recurrent endometrial cancer

Prof Matthew Powell - Washington University School of Medicine, Missouri, USA

Dostarlimab chemo combo for primary advanced or recurrent endometrial cancer ( Prof Matthew Powell - Washington University School of Medicine, Missouri, USA )

2L triple metronomic chemo has an OS and PFS advantage over systemic therapy...

Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital...

2L triple metronomic chemo has an OS and PFS advantage over systemic therapy for head and neck cancer ( Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital, Ahmedabad, India )

Single cilta-cel infusion improved PFS vs SOC in lenalidomide-refractory MM

Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA

$Single cilta-cel infusion improved PFS vs SOC in lenalidomide-refractory MM ( Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA )$

mRCC: Atezolizumab after progression with prior ICI treatment no benefit and...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Effectiveness of a cardiovascular health EHR application for cancer survivors...

Prof Kathryn Weaver - Wake Forest School of Medicine, Winston-Salem, USA

Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice ( Prof Kathryn Weaver - Wake Forest School of Medicine, Winston-Salem, USA )

More from ecancer